Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ziftomenib for adult patients with relapsed or refractory acute myeloid leukemia with a ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

Annamycin, a chemotherapy drug with zero cardiotoxicity, is being tested for relapsed or refractory AML in the phase 3 MIRACLE trial. The trial, active in the U.S., Europe, and the Middle East, ...

AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...

Molecular Partners AG announced positive results from a Phase 1/2a trial of its tetraspecific T-cell engager MP0533 for relapsed/refractory acute myeloid leukemia (AML) during the 30th EHA Congress.

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving AML care beyond one-size-fits-all induction and transplant algorithms.

LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single ...

Kura Oncology and Kyowa Kirin announce FDA acceptance of ziftomenib NDA for relapsed/refractory AML, targeting a November 2025 decision. Kura Oncology and Kyowa Kirin announced that the FDA has ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Therapy-related MDS/AML is an increasingly recognized, often fatal late complication after prolonged ...